Glycated hemoglobin A_1c (HbA_1c) and diabetes: a new era?

References

• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34(Suppl 1):S62-9
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Executive summary: standards of medical care in diabetes – 2011. Diabetes Care 2011;34(Suppl 1):S4-10
   PubMedGoogle Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62-9
   PubMed Web of Science ®Google Scholar
• DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• DCCT Research Group. Feasibility of centralized measurements of glycated haemoglobin in the (DCCT): a multicenter study. Clin Chem 1987;33:2267-71
   PubMed Web of Science ®Google Scholar
• Available at: www.easd.org – statements [Last accessed 11 September, 2011]
   Google Scholar
• Davidson MB. Diagnosing diabetes with glucose criteria: worshiping a false God. Diabetes Care 2011;34:524-6
   PubMed Web of Science ®Google Scholar
• Sacks DB. A1C versus glucose testing: a comparison. Diabetes Care 2011;34:518-23
   PubMed Web of Science ®Google Scholar
• International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34
   PubMed Web of Science ®Google Scholar
• Available at: http://www.ifcc.org/PDF/SummaryManufacturerMeetingImplementation_HbA1c_Standardization.pdf [Last accessed 11 September, 2011]
   Google Scholar
• John WG, Mosca A, Weykamp C, et al. HbA1c standardisation: history, science and politics. Clin Biochem Rev 2007;28:163-8
   PubMedGoogle Scholar
• Marshall SM. Standardization of HbA1c: good or bad? Nat Rev Endocrinol 2010;6:408-11
   PubMed Web of Science ®Google Scholar
• Mann DM, Carson AP, Shimbo D, et al. Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. Diabetes Care 2010;33:2190-5
   PubMed Web of Science ®Google Scholar
• Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988–2006. Diabetes Care 2010;33:562-8
   PubMed Web of Science ®Google Scholar
• Lorenzo C, Wagenknecht LE, Hanley AJ, et al. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care 2010;33:2104-9
   PubMed Web of Science ®Google Scholar
• Ng JM, Cooke M, Bhandari S, et al. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. Diabetes Care 2010;33:2310-13
   PubMed Web of Science ®Google Scholar
• Suzuki K, Yagi K, Oka R, et al. Relationships of serum haptoglobin concentration with HbA1c and glycated albumin concentrations in Japanese type 2 diabetic patients. Clin Chem Lab Med 2009;47:70-4
   PubMed Web of Science ®Google Scholar
• Little RR, Roberts WL. A review of variant hemoglobins interfering with haemoglobin A1c measurement. J Diabetes Sci Technol 2009;3:446-51
   PubMedGoogle Scholar
• Higgins T, Stewart D, Boehr E. Challenges in HbA1c analysis and reporting: an interesting case illustrating the many pitfalls. Clin Biochem 2008;41:1104-6
   PubMed Web of Science ®Google Scholar
• Gunton JE, McElduff A. Hemoglobinopathies and HbA(1c) measurement. Diabetes Care. 2000;23:1197-8
   PubMed Web of Science ®Google Scholar
• Abadie JM, Koelsch AA. Performance of the Roche second generation haemoglobin A1c immunoassay in the presence of HB-S or HB-C traits. Ann Clin Lab Sci 2008;38:31-6
   PubMed Web of Science ®Google Scholar
• Al-Khoury S, Afzali B, Shah N, et al. Anaemia in diabetic patients with chronic kidney disease – prevalence and predictors. Diabetologia 2006;49:1183-9
   PubMed Web of Science ®Google Scholar
• Thomas S, Rampersad M. Anaemia in diabetes. Acta Diabetol 2004;41(Suppl 1):S13-17
   PubMedGoogle Scholar
• Kosecki SM, Rodgers PT, Adams MB. Glycemic monitoring in diabetics with sickle cell plus beta-thalassemia hemoglobinopathy. Ann Pharmacother 2005;39:1557-60
   PubMed Web of Science ®Google Scholar
• Koga M, Hashimoto K, Murai J, et al. Usefulness of glycated albumin as an indicator of glycemic control status in patients with hemolytic anemia. Clin Chim Acta 2011;412:253-7
   PubMed Web of Science ®Google Scholar
• Schnedl WJ, Krause R, Halwachs-Baumann G, et al. Evaluation of HbA1c determination methods in patients with hemoglobinopathies. Diabetes Care 2000;23:339-44
   PubMed Web of Science ®Google Scholar
• Koga M, Otsuki M, Matsumoto S, et al. Negative association of obesity and its related chronic inflammation with serum glycated albumin but not glycated hemoglobin levels. Clin Chim Acta 2007;378:48-52
   PubMed Web of Science ®Google Scholar
• Koga M, Saito H, Mukai M, et al. Serum glycated albumin levels are influenced by smoking status, independent of plasma glucose levels. Acta Diabetol 2009;46:141-4
   PubMed Web of Science ®Google Scholar
• Koga M, Murai J, Saito H, et al. Serum glycated albumin, but not glycated haemoglobin, is low in relation to glycemia in hyperuricemic men. Acta Diabetol 2010;47:173-7
   PubMed Web of Science ®Google Scholar
• Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001;47:153-63
   PubMed Web of Science ®Google Scholar
• Cohen RM, Holmes YR, Chenier TC, et al. Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care 2003;26:163-7
   PubMed Web of Science ®Google Scholar
• Chalew SA, McCarter RJ, Thomas J, et al. A comparison of the glycosylation gap and hemoglobin glycation index in patients with diabetes. J Diabetes Complications 2005;19:218-22
   PubMed Web of Science ®Google Scholar
• Leslie RD, Cohen RM. Biologic variability in plasma glucose, hemoglobin A1c, and advanced glycation end products associated with diabetes complications. J Diabetes Sci Technol 2009;3:635-43
   PubMedGoogle Scholar
• Park CY, Park SE, Bae JC, et al. Prevalence of and risk factors for diabetic retinopathy in Koreans with type II diabetes: baseline characteristics of Seoul Metropolitan City–Diabetes Prevention Program (SMC-DPP) participants. Br J Ophthalmol 2011 Jul 20 [Epub ahead of print]
   Google Scholar
• Sabanayagam C, Liew G, Tai ES, et al. Relationship between glycated haemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes? Diabetologia 2009;52:1279-89
   PubMed Web of Science ®Google Scholar
• Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008;31:2198-202
   PubMed Web of Science ®Google Scholar
• Lachin JM, Genuth S, Nathan DM, et al.; DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial – revisited. Diabetes. 2008;57:995-1001
   PubMed Web of Science ®Google Scholar
• Thomaseth K, Pacini G, Morelli P, et al. Importance of glycemic control on the course of glomerular filtration rate in type 2 diabetes with hypertension and microalbuminuria under tight blood pressure control. Nutr Metab Cardiovasc Dis 2008;18:632-8
   PubMed Web of Science ®Google Scholar
• Jurado J, Ybarra J, Romeo JH, et al. Clinical screening and diagnosis of diabetic polyneuropathy: the North Catalonia Diabetes Study. Eur J Clin Invest 2009;39:183-9
   PubMed Web of Science ®Google Scholar
• El-Salem K, Ammari F, Khader Y, et al. Elevated glycosylated hemoglobin is associated with subclinical neuropathy in neurologically asymptomatic diabetic patients: a prospective study. J Clin Neurophysiol 2009;26:50-3
   PubMed Web of Science ®Google Scholar
• Giorda CB, Cioffi G, de Simone G, et al. Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. Eur J Cardiovasc Prev Rehabil 2011 Feb 22 [Epub ahead of print]
   Google Scholar
• Marso SP, Kennedy KF, House JA, et al. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diab Vasc Dis Res 2010;7:119-30
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-72
   PubMed Web of Science ®Google Scholar
• Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006;152:27-38
   PubMed Web of Science ®Google Scholar
• Simmons RK, Sharp S, Boekholdt SM, et al. Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer–Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med 2008;168:1209-16
   PubMed Web of Science ®Google Scholar
• Control Group, Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-98
   PubMed Web of Science ®Google Scholar
• Ma J, Yang W, Fang N, et al. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis. Nutr Metab Cardiovasc Dis 2009;19:596-603
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Markuson M, Hanson D, Anderson J, et al. The relationship between hemoglobin A(1c) values and healing time for lower extremity ulcers in individuals with diabetes. Adv Skin Wound Care 2009;22:365-72
   PubMed Web of Science ®Google Scholar
• Myint PK, Sinha S, Wareham NJ, et al. Glycated hemoglobin and risk of stroke in people without known diabetes in the European Prospective Investigation into Cancer (EPIC)–Norfolk prospective population study: a threshold relationship? Stroke 2007;38:271-5
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Available at: http://www.sge-ssn.ch/fileadmin/pdf/500-fuer_experten/40-grundlagendokumente/4ernaehrung_gesundheit/Global_Guidelines_for_Type_2_Diabetes_International_Diabetes_Federation.pdf [Last accessed 11 September, 2011]
   Google Scholar
• Davila EP, Florez H, Trepka MJ, et al. Strict glycemic control and mortality risk among US adults with type 2 diabetes. J Diabetes Complications 2011 Jun 7 [Epub ahead of print]
   Google Scholar
• O’Keefe JH, Abuannadi M, Lavie CJ, et al. Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc 2011;86:128-38
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 2010;7:369-75
   PubMed Web of Science ®Google Scholar
• Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009;151:394-403
   PubMed Web of Science ®Google Scholar
• Alam T, Weintraub N, Weinreb J. What is the proper use of hemoglobin A1c monitoring in the elderly? J Am Med Dir Assoc 2005;6:200-4
   PubMedGoogle Scholar
• Fonseca V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr Med Res Opin 2003;19:635-41
   PubMed Web of Science ®Google Scholar
• Heianza Y, Hara S, Arase Y, et al. HbA1c 5.7–6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet 2011;378:147-55
   PubMed Web of Science ®Google Scholar
• Schaufler TM, Wolff M. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany. Appl Health Econ Health Policy 2010;8:191-202
   PubMedGoogle Scholar
• Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011;378:156-67
   PubMed Web of Science ®Google Scholar
• Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008;336:1180-5
   PubMed Web of Science ®Google Scholar
• Waugh N, Scotland G, McNamee P, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007;11:iii-iv, ix-xi, 1-125
   Web of Science ®Google Scholar
• Horton ES. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials. Obesity (Silver Spring). 2009;17(Suppl 3):S43-8
   PubMed Web of Science ®Google Scholar
• Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783-9
   PubMed Web of Science ®Google Scholar
• NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-90
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Gossios TD, et al.; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22
   PubMed Web of Science ®Google Scholar